Haseeb Anwar Dad1,2, Asra Shanzeh Shabbir3,4, Saman Ali2,4, Tariq Mahmood2. 1. Zhejiang University College of Pharmaceutical Sciences, Department of Pharmaceutics, Hangzhou, China. 2. University of Central Punjab Faculty of Pharmacy, Department of Pharmaceutics, Lahore, Pakistan. 3. Punjab University College of Pharmacy, Department of Pharmaceutics, Lahore, Pakistan. 4. Lahore Medical and Dental College Lahore Pharmacy College, Department of Pharmaceutics, Lahore, Pakistan.
Abstract
OBJECTIVES: The objective of this research was to fabricate, characterize, and optimize fluoxetine laden orodispersible film (ODF), in enhancing dosage forms options for the pediatric population suffering from incapacitating psychotic disorders of selective mutism and obsessive-compulsive disorder, which will be ultimately beneficial in enhancing compliance factor and the quality of pharmacotherapy. MATERIALS AND METHODS: Solvent casting technique was used to formulate the ODF formed by natural hydrophilic polymers matrix of hydroxypropyl methylcellulose E15 and pullulan. Propylene glycol as plasticizing agent imparted satisfactory tenacity and flexibility to ODFs. Fourier transform infrared spectroscopy studies were performed to investigate any potential compatibility, and the results revealed no potential interaction between fluoxetine and excipients. Developed ODFs were evaluated for physicochemical properties, content uniformity, in vitro disintegration time, and in vitro dissolution time studies. Results: The experimental data. RESULTS: The experimental data suggested that different polymer concentrations had a complex effect on content uniformity, in vitro disintegration time, and cumulative percentage drug release from the ODFs. TF7 was the most optimized formulation with a disintegration time of 10.66 sec and 99.37% drug release within 3 min. Additionally, the most optimized fluoxetine ODF was submitted to a Universal Testing Machine for tensile strength and percentage elongation determination. It was also further evaluated by thermogravimetric analysis, scanning electron microscopy and X-ray diffraction. CONCLUSION: Fluoxetine ODFs of good pharmaceutical quality can be prepared on a small scale. Therefore, the perspective of using fluoxetine ODFs for individualized pharmacotherapy to ameliorate the compliance issues in selective mutism and OCD pediatric patients can be considered.
OBJECTIVES: The objective of this research was to fabricate, characterize, and optimize fluoxetine laden orodispersible film (ODF), in enhancing dosage forms options for the pediatric population suffering from incapacitating psychotic disorders of selective mutism and obsessive-compulsive disorder, which will be ultimately beneficial in enhancing compliance factor and the quality of pharmacotherapy. MATERIALS AND METHODS: Solvent casting technique was used to formulate the ODF formed by natural hydrophilic polymers matrix of hydroxypropyl methylcellulose E15 and pullulan. Propylene glycol as plasticizing agent imparted satisfactory tenacity and flexibility to ODFs. Fourier transform infrared spectroscopy studies were performed to investigate any potential compatibility, and the results revealed no potential interaction between fluoxetine and excipients. Developed ODFs were evaluated for physicochemical properties, content uniformity, in vitro disintegration time, and in vitro dissolution time studies. Results: The experimental data. RESULTS: The experimental data suggested that different polymer concentrations had a complex effect on content uniformity, in vitro disintegration time, and cumulative percentage drug release from the ODFs. TF7 was the most optimized formulation with a disintegration time of 10.66 sec and 99.37% drug release within 3 min. Additionally, the most optimized fluoxetine ODF was submitted to a Universal Testing Machine for tensile strength and percentage elongation determination. It was also further evaluated by thermogravimetric analysis, scanning electron microscopy and X-ray diffraction. CONCLUSION: Fluoxetine ODFs of good pharmaceutical quality can be prepared on a small scale. Therefore, the perspective of using fluoxetine ODFs for individualized pharmacotherapy to ameliorate the compliance issues in selective mutism and OCD pediatric patients can be considered.
Authors: Justin A Barterian; Joel M Sanchez; Jed Magen; Allison K Siroky; Brittany L Mash; John S Carlson Journal: J Psychiatr Pract Date: 2018-01 Impact factor: 1.325
Authors: Michael R Liebowitz; Samuel M Turner; John Piacentini; Deborah C Beidel; Susan R Clarvit; Sharon O Davies; Flemming Graae; Margaret Jaffer; Shu-Hsing Lin; Floyd R Sallee; Andrew B Schmidt; H Blair Simpson Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-12 Impact factor: 8.829
Authors: Diana A van Riet-Nales; Alfred F A M Schobben; Herman Vromans; Toine C G Egberts; Carin M A Rademaker Journal: Arch Dis Child Date: 2016-03-15 Impact factor: 3.791